957793-95-2

Usage

Uses

Used in Pharmaceutical Industry:
cis-3-Aminocyclobutanecarboxylic acid tert-butyl ester is used as a building block for the synthesis of pharmaceuticals and other organic compounds. Its versatility as an intermediate allows for the development of new drugs and biologically active molecules.
Used in Organic Synthesis:
cis-3-Aminocyclobutanecarboxylic acid tert-butyl ester is used as a protective group for the carboxylic acid functional group in organic synthesis. The tert-butyl ester group can be easily removed under mild acidic conditions, making it a useful tool for protecting the carboxylic acid during the synthesis process.

InChI:InChI=1/C9H17NO2/c1-9(2,3)12-8(11)6-4-7(10)5-6/h6-7H,4-5,10H2,1-3H3/t6-,7+

Upstream product

• 1192547-85-5 tert-butyl 3-azidocyclobutane carboxylate 
• 1311158-43-6 trans-tert-butyl (1r,3r)-3-hydroxycyclobutane-1-carboxylate 
• 154748-49-9 3-(tert-butyloxycarbonylamino)cyclobutan-1-one 

Relevant academic research and scientific papers

METHODS OF TREATING PULMONARY DISEASES AND DISORDERS

The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.

COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY

The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (I) or (II).

COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY

The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.

AMINO ACID COMPOUNDS

[Problem] To provide novel compounds that are S1P1 receptor agonists and exhibit an immunosuppressive activities by inducing lymphocyte sequestration in secondary lymphoid tissues. In addition, to provide a pharmaceutical agent which comprises the compounds as an effective component, in particular to provide a therapeutic and/or prophylactic agent for an autoimmune disease and the like. [Solving Means] Amino acid compounds that are represented by the following Formula (1) are provided